Variable | Total Cohort (n = 65); n (%) | MDACC (n = 14); n (%) |
---|---|---|
MGFA classification | ||
I | 8 (12) | 1 (7) |
II | 14 (22) | 5 (36) |
III | 8 (12) | 0 |
IV | 4 (6) | 0 |
V | 29 (45) | 7 (50) |
Clinical presentation | ||
Ptosis | 49 (75) | 11 (79) |
Dyspnea | 40 (62) | 10 (71) |
Limb weakness | 36 (55) | 7 (50) |
Dysphagia | 31 (48) | 7 (50) |
Diplopia | 27 (42) | 4 (29) |
Neck weakness | 22 (34) | 5 (36) |
Myalgias | 13 (20) | 4 (29) |
Dysarthria | 8 (12) | 3 (21) |
Facial weakness | 8 (12) | 3 (21) |
Blurry vision | 7 (11) | 4 (29) |
Dysphonia | 7 (11) | 4 (29) |
Generalized weakness | 6 (9) | 2 (14) |
Nasal speech/weakness of the palatal muscles | 6 (9) | 1 (7) |
Incontinence | 2 (3) | 1 (7) |
Diagnostic tools | ||
Auto antibody panel positive titers | ||
Anti-AChR | 37/56 (66) | 5/10 (50) |
Anti-Striated muscle | 12/18 (67) | 6/9 (67) |
Muscle enzymes elevation | ||
CPK | 41/49 (84) | 9/10 (90) |
Troponin | 13/14 (93) | 6/7 (86) |
Edrophonium test positive | 4/5 (80)b | 0 |
Ice pack test positive | 2/4 (50)b | 0 |
Electrodiagnostic studies (skeletal muscle EMG, RNS, NCS) | ||
MG | 16/37 (43)c | 3/9 (33) |
Myopathy | 6/37 (16)d | 2/9 (22) |
MG and myopathy | 6/37 (16)d | 4/9 (44) |
Polyneuropathy | 3/37 (8) | 0/9 |
No pathologic findings | 6/37 (16) | 0/9 |
Treatment of MG | ||
Corticosteroids | 59/63e (94) | 13/13 (100) |
Acetylcholinesterase inhibitors | 32/63e (51) | 7/13 (54) |
IVIG | 30/63e (48) | 9/13 (69) |
Plasmapheresis | 28/63e (44) | 8/13 (62) |
Other IST (MMF, rituximab, infliximab or tacrolimus) | 10/63e (16) | 6/13 (46) |
IA | 1/63e (2) | 1/13 (8) |
ICI holding/discontinuation | 61/63e (97) | 12/13 (92) |
MG outcome | ||
Complete resolution | 12/62e,f (19) | 6/13 (46) |
Improvement | 34/62e,f (55) | 5/13 (39) |
Deterioration | 16/62e,f (26) | 2/13 (15) |
Death | 24 (37) | 5/14 (36) |
MG complications | 15 (23)g | 3/14 (21) |
Cancer progression | 4 (6) | 2/14 (14) |
Other comorbidities | 3 (5)h | 0 |
Unspecified | 2 (3) | 0 |